Trial Profile
Multi-center, Randomized, Evaluator-blind, Active-controlled, Study to Determine the Safety, Tolerability, and Efficacy of Multiple Daily Doses of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2015
Price :
$35
*
At a glance
- Drugs LFF 571 (Primary) ; Vancomycin
- Indications Clostridium difficile infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 04 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jun 2013 Planned end date changed from 1 May 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 15 Sep 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-000947-26)